Holen Sie sich die Stockscreener-App
23.57
7.53%
1.65
Handel nachbörslich:
23.46
-0.11
-0.47%
Schlusskurs vom Vortag:
$21.92
Offen:
$22.04
24-Stunden-Volumen:
83,745
Relative Volume:
0.82
Marktkapitalisierung:
$341.20M
Einnahmen:
$1.80M
Nettoeinkommen (Verlust:
$1.76B
KGV:
0.1986
EPS:
118.674
Netto-Cashflow:
$-149.23M
1W Leistung:
+12.35%
1M Leistung:
+8.27%
6M Leistung:
+79.38%
1J Leistung:
+108.58%
1-Tages-Spanne:
$22.04
$23.59
1-Wochen-Bereich:
$20.55
$23.59
52-Wochen-Spanne:
$10.80
$25.29
Inhibrx Biosciences Inc Stock (INBX) Company Profile
Firmenname
Inhibrx Biosciences Inc
Sektor
Branche
Telefon
(858) 795-4220
Adresse
11025 N. TORREY PINES ROAD, SUITE 140, LA JOLLA
Vergleichen Sie INBX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INBX
Inhibrx Biosciences Inc
|
23.57 | 317.31M | 1.80M | 1.76B | -149.23M | 118.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Inhibrx Biosciences Inc Stock (INBX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-07-23 | Eingeleitet | JMP Securities | Mkt Perform |
| 2024-01-23 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-03-16 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-09-21 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-09-14 | Eingeleitet | Credit Suisse | Outperform |
| 2020-09-14 | Eingeleitet | Evercore ISI | Outperform |
Alle ansehen
Inhibrx Biosciences Inc Aktie (INBX) Neueste Nachrichten
Inhibrx Biosciences: Navigating the High-Stakes Gamble of Early-Stage Biotech Innovation - AInvest
Inhibrx Q2 Results: $186M Cash Runway as Two Major Cancer Drug Trials Near Data Readouts - Stock Titan
How to monitor Inhibrx Biosciences Inc. with trend dashboardsJuly 2025 Rallies & Technical Pattern Alert System - Newser
How to integrate Inhibrx Biosciences Inc. into portfolio analysis toolsTrade Risk Report & Risk Adjusted Buy and Sell Alerts - Newser
Sentiment analysis tools applied to Inhibrx Biosciences Inc.Free Weekly Chart Analysis With Entry Advice - Newser
Reversal indicators forming on Inhibrx Biosciences Inc. stockJuly 2025 Sentiment & Accurate Technical Buy Alerts - Newser
Inhibrx Biosciences Inc. stock trend outlook and recovery pathQuarterly Earnings Summary & Reliable Price Breakout Signals - Newser
Inhibrx Biosciences Inc. stock prediction for this weekSector Rotation and Stock Opportunity Analysis - Newser
Is Inhibrx Biosciences Inc. stock ready for a breakoutAI Triggered Buy Zone Forecast System - Newser
Intrinsic Value of Inhibrx Biosciences Inc. Stock: Is It Undervalued or OvervaluedFree Stable Entry High Return Opportunities - Newser
Tools to assess Inhibrx Biosciences Inc.’s risk profileTrade Safety Matrix for Conservative Traders - Newser
How Inhibrx Biosciences Inc. stock performs during market volatilityFree ROI Boosting Trade Opportunity Calendar - Newser
Does Inhibrx Biosciences Inc. qualify in momentum factor screeningFree ROI Driven Equity Selection With Safety - Newser
Visual trend scoring systems applied to Inhibrx Biosciences Inc.Free Sector Rotation Based Trading Opportunities - Newser
Reversal Traders Monitor Inhibrx Biosciences Inc. for EntryReal-Time Market Sentiment Tracking Gains Momentum - metal.it
What makes Inhibrx Biosciences Inc. stock price move sharplyFree Smart Trend Trading with Weekly Signals - Newser
New Product Launches: Will They Boost Inhibrx Biosciences Inc. Stock in 2025Strong Buy Signal Summary with Entry Zone - Newser
What’s the recovery path for long term holders of Inhibrx Biosciences Inc.Buy Signal Forecast With Short-Term Data - Newser
Inhibrx Biosciences Inc expected to post a loss of $2.76 a shareEarnings Preview - TradingView
Inhibrx Biosciences Inc. Stock Fails to Break Resistance Traders ReactTrade Setups With Clear Risk Limits Highlighted - beatles.ru
Inhibrx Biosciences Inc. stock trendline breakdownSwing Trade Watchlist with Entry Zones - Newser
Why Inhibrx Biosciences Inc. stock attracts strong analyst attentionDeep Stock Performance and Volatility Analysis - Newser
Combining price and volume data for Inhibrx Biosciences Inc.Buy and Hold Return Summary with Charts - Newser
Risk adjusted return profile for Inhibrx Biosciences Inc. analyzedPortfolio Positioning Strategy With Timing - Newser
Is Now a Good Time to Reenter Inhibrx Biosciences Inc.ROI Boosting Trade Opportunity Calendar Published - beatles.ru
What are analysts’ price targets for Inhibrx Biosciences Inc. in the next 12 monthsIdentify winners with top-tier analysis - Jammu Links News
Inhibrx Biosciences Inc. Reversal Rally May Surprise BearsExit Ready Momentum Stock Watchlist Expanded - metal.it
Will Inhibrx Biosciences Inc. outperform the marketFree Community Entry Consensus Trade Ideas - Newser
Inhibrx Biosciences Inc. Stock Analysis and ForecastAccelerated capital growth - Jammu Links News
What analysts say about Inhibrx Biosciences Inc. stockGet real-time alerts on high-potential stocks - Jammu Links News
Does Inhibrx Biosciences Inc. stock perform well during market downturnsTriple-digit wealth increases - Jammu Links News
Is Inhibrx Biosciences Inc. stock overvalued or undervaluedAmplify your gains with low-risk picks - Jammu Links News
What moving averages say about Inhibrx Biosciences Inc.2-Day Signal Watch with Forecast Outcome - Newser
Inhibrx Biosciences Inc. Company Revenue and Profit Trends: A Deep DiveWeekly Stock Market Strategy Summary - Newser
What is the risk reward ratio of investing in Inhibrx Biosciences Inc. stockConsistent high-performance stocks - Jammu Links News
Finanzdaten der Inhibrx Biosciences Inc-Aktie (INBX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):